Target type: biologicalprocess
Any process that increases the frequency, rate or extent of the platelet-derived growth factor receptor signaling pathway. [GOC:dph, GOC:hjd, GOC:tb]
Positive regulation of platelet-derived growth factor receptor (PDGFR) signaling pathway is a crucial cellular process that controls the growth, proliferation, and differentiation of various cell types, primarily fibroblasts, smooth muscle cells, and certain immune cells. This pathway is activated upon binding of platelet-derived growth factor (PDGF) ligands to their cognate PDGFRs, which are tyrosine kinase receptors.
The process can be summarized in the following steps:
1. **Ligand Binding and Receptor Dimerization:** PDGF ligands, such as PDGF-AA, -AB, -BB, -CC, and -DD, bind to their respective PDGFRs (PDGFRα and PDGFRβ), leading to receptor dimerization. This dimerization brings together the intracellular tyrosine kinase domains of the receptors.
2. **Tyrosine Kinase Activation:** The dimerization event triggers autophosphorylation of tyrosine residues within the kinase domains of the receptors. This phosphorylation activates the kinase activity of the receptors.
3. **Recruitment of Signaling Molecules:** The phosphorylated tyrosine residues serve as docking sites for various signaling molecules, including adaptor proteins (e.g., Grb2, Shc), phospholipase Cγ (PLCγ), and phosphatidylinositol 3-kinase (PI3K).
4. **Activation of Downstream Signaling Pathways:** The recruited signaling molecules initiate a cascade of downstream signaling events:
* **Ras-MAPK Pathway:** Grb2 and Shc activate the Ras-mitogen-activated protein kinase (MAPK) pathway, leading to increased transcription of genes involved in cell growth, proliferation, and survival.
* **PI3K-Akt Pathway:** PI3K activates the phosphatidylinositol 3-kinase (PI3K)-Akt pathway, promoting cell survival, growth, and angiogenesis.
* **PLCγ Pathway:** PLCγ hydrolyzes phosphatidylinositol 4,5-bisphosphate (PIP2) into diacylglycerol (DAG) and inositol trisphosphate (IP3), activating protein kinase C (PKC) and calcium signaling, respectively.
5. **Cellular Responses:** The activation of these signaling pathways ultimately leads to a range of cellular responses, including:
* **Cell Proliferation:** Stimulation of DNA synthesis and cell division.
* **Cell Survival:** Inhibition of apoptosis (programmed cell death).
* **Cell Migration and Differentiation:** Regulation of cell movement and specialization.
* **Extracellular Matrix Remodeling:** Production and degradation of components of the extracellular matrix.
6. **Negative Regulation:** The PDGFR signaling pathway is tightly regulated by feedback mechanisms to prevent excessive signaling and maintain cellular homeostasis. These mechanisms include:
* **Protein Phosphatases:** Dephosphorylate tyrosine residues on PDGFRs, deactivating the receptors.
* **Ubiquitination and Degradation:** PDGFRs are targeted for degradation by the ubiquitin-proteasome system.
* **Negative Feedback Loops:** Activated signaling components, such as Akt, can inhibit upstream signaling events, creating a feedback loop that dampens pathway activity.
In summary, positive regulation of PDGFR signaling pathway plays a crucial role in a variety of physiological processes, including tissue development, wound healing, angiogenesis, and immune responses. However, aberrant activation of this pathway can contribute to various diseases, including cancer, fibrosis, and atherosclerosis.'
"
Protein | Definition | Taxonomy |
---|---|---|
Tissue factor | A tissue factor that is encoded in the genome of human. [PRO:WCB, UniProtKB:P13726] | Homo sapiens (human) |
Coagulation factor VII | A coagulation factor VII that is encoded in the genome of human. [PRO:DNx, UniProtKB:P08709] | Homo sapiens (human) |
Compound | Definition | Classes | Roles |
---|---|---|---|
niacinamide | nicotinamide : A pyridinecarboxamide that is pyridine in which the hydrogen at position 3 is replaced by a carboxamide group. | pyridine alkaloid; pyridinecarboxamide; vitamin B3 | anti-inflammatory agent; antioxidant; cofactor; EC 2.4.2.30 (NAD(+) ADP-ribosyltransferase) inhibitor; EC 3.5.1.98 (histone deacetylase) inhibitor; Escherichia coli metabolite; geroprotector; human urinary metabolite; metabolite; mouse metabolite; neuroprotective agent; Saccharomyces cerevisiae metabolite; Sir2 inhibitor |
benzamide | benzamide : An aromatic amide that consists of benzene bearing a single carboxamido substituent. The parent of the class of benzamides. | benzamides | |
benzamidine | benzamidine : A carboxamidine that is benzene carrying an amidino group. benzamidine: RN given refers to parent cpd | benzenes; carboxamidine | serine protease inhibitor |
diazoxide | diazoxide : A benzothiadiazine that is the S,S-dioxide of 2H-1,2,4-benzothiadiazine which is substituted at position 3 by a methyl group and at position 7 by chlorine. A peripheral vasodilator, it increases the concentration of glucose in the plasma and inhibits the secretion of insulin by the beta- cells of the pancreas. It is used orally in the management of intractable hypoglycaemia and intravenously in the management of hypertensive emergencies. Diazoxide: A benzothiadiazine derivative that is a peripheral vasodilator used for hypertensive emergencies. It lacks diuretic effect, apparently because it lacks a sulfonamide group. | benzothiadiazine; organochlorine compound; sulfone | antihypertensive agent; beta-adrenergic agonist; bronchodilator agent; cardiotonic drug; diuretic; K-ATP channel agonist; sodium channel blocker; sympathomimetic agent; vasodilator agent |
valproic acid | valproic acid : A branched-chain saturated fatty acid that comprises of a propyl substituent on a pentanoic acid stem. Valproic Acid: A fatty acid with anticonvulsant and anti-manic properties that is used in the treatment of EPILEPSY and BIPOLAR DISORDER. The mechanisms of its therapeutic actions are not well understood. It may act by increasing GAMMA-AMINOBUTYRIC ACID levels in the brain or by altering the properties of VOLTAGE-GATED SODIUM CHANNELS. | branched-chain fatty acid; branched-chain saturated fatty acid | anticonvulsant; antimanic drug; EC 3.5.1.98 (histone deacetylase) inhibitor; GABA agent; neuroprotective agent; psychotropic drug; teratogenic agent |
entinostat | benzamides; carbamate ester; primary amino compound; pyridines; substituted aniline | antineoplastic agent; apoptosis inducer; EC 3.5.1.98 (histone deacetylase) inhibitor | |
isocarbostyril | isoquinolinone : An isoquinoline containing one or more oxo groups. | isoquinolines | |
oleanolic acid | hydroxy monocarboxylic acid; pentacyclic triterpenoid | plant metabolite | |
dichlorobenzyl alcohol | 2,4-dichlorobenzyl alcohol : A member of the class of benzyl alcohols that is benzyl alcohol in which the hydrogens at positions 2 and 4 are replaced by chlorines. | benzyl alcohols; dichlorobenzene | antiseptic drug |
canadine | canadine : A berberine alkaloid that is 5,8,13,13a-tetrahydro-6H-[1,3]dioxolo[4,5-g]isoquino[3,2-a]isoquinoline substituted by methoxy groups at positions 9 and 10. canadine: RN given refers to cpd without isomeric designation; structure | aromatic ether; berberine alkaloid; organic heteropentacyclic compound; oxacycle | |
mifepristone | Mifepristone: A progestational and glucocorticoid hormone antagonist. Its inhibition of progesterone induces bleeding during the luteal phase and in early pregnancy by releasing endogenous prostaglandins from the endometrium or decidua. As a glucocorticoid receptor antagonist, the drug has been used to treat hypercortisolism in patients with nonpituitary CUSHING SYNDROME. | 3-oxo-Delta(4) steroid; acetylenic compound; tertiary amino compound | abortifacient; contraceptive drug; hormone antagonist; synthetic oral contraceptive |
tetrahydropalmatine | an (S)-7,8,13,14-tetrahydroprotoberberine; berberine alkaloid; organic heterotetracyclic compound | adrenergic agent; dopaminergic antagonist; non-narcotic analgesic | |
hederagenin | dihydroxy monocarboxylic acid; pentacyclic triterpenoid; sapogenin | plant metabolite | |
echinocystic acid | triterpenoid | ||
1-aminoisoquinoline | |||
5-chloroindole-2-carboxylate | 5-chloroindole-2-carboxylate: N-methyl-D-aspartate glycine site antagonist | indolyl carboxylic acid | |
5-chloroindole | 5-chloroindole: a positive allosteric modulator of the 5-HT3 receptor | ||
corydalmine | corydalmine: antagonizes dopamine receptors; structure given in first source; RN given refers to (S)-isomer | ||
melagatran | azetidines; carboxamidine; dicarboxylic acid monoamide; non-proteinogenic alpha-amino acid; secondary amino compound | anticoagulant; EC 3.4.21.5 (thrombin) inhibitor; serine protease inhibitor | |
razaxaban | razaxaban: structure in first source | ||
trichostatin a | trichostatin A: chelates zinc ion in the active site of histone deacetylases, resulting in preventing histone unpacking so DNA is less available for transcription; do not confuse with TRICHOSANTHIN which is a protein; found in STREPTOMYCES | antibiotic antifungal agent; hydroxamic acid; trichostatin | bacterial metabolite; EC 3.5.1.98 (histone deacetylase) inhibitor; geroprotector |
arachidonic acid | arachidonate : A long-chain fatty acid anion resulting from the removal of a proton from the carboxy group of arachidonic acid. icosa-5,8,11,14-tetraenoic acid : Any icosatetraenoic acid with the double bonds at positions 5, 8, 11 and 14. | icosa-5,8,11,14-tetraenoic acid; long-chain fatty acid; omega-6 fatty acid | Daphnia galeata metabolite; EC 3.1.1.1 (carboxylesterase) inhibitor; human metabolite; mouse metabolite |
palmitoleic acid | hexadecenoate : A long-chain unsaturated fatty acid anion that is the conjugate base of hexadecenoic acid, obtained by deprotonation of the carboxy group; major species at pH 7.3. | hexadec-9-enoic acid | algal metabolite; Daphnia galeata metabolite; EC 3.1.1.1 (carboxylesterase) inhibitor; Escherichia coli metabolite; human blood serum metabolite |
oleic acid | oleic acid : An octadec-9-enoic acid in which the double bond at C-9 has Z (cis) stereochemistry. Oleic Acid: An unsaturated fatty acid that is the most widely distributed and abundant fatty acid in nature. It is used commercially in the preparation of oleates and lotions, and as a pharmaceutical solvent. (Stedman, 26th ed) | octadec-9-enoic acid | antioxidant; Daphnia galeata metabolite; EC 3.1.1.1 (carboxylesterase) inhibitor; Escherichia coli metabolite; mouse metabolite; plant metabolite; solvent |
eicosapentaenoic acid | all-cis-5,8,11,14,17-icosapentaenoic acid : An icosapentaenoic acid having five cis-double bonds at positions 5, 8, 11, 14 and 17. icosapentaenoic acid : Any straight-chain, C20 polyunsaturated fatty acid having five C=C double bonds. | icosapentaenoic acid; omega-3 fatty acid | anticholesteremic drug; antidepressant; antineoplastic agent; Daphnia galeata metabolite; fungal metabolite; micronutrient; mouse metabolite; nutraceutical |
curcumin | curcumin : A beta-diketone that is methane in which two of the hydrogens are substituted by feruloyl groups. A natural dyestuff found in the root of Curcuma longa. Curcumin: A yellow-orange dye obtained from tumeric, the powdered root of CURCUMA longa. It is used in the preparation of curcuma paper and the detection of boron. Curcumin appears to possess a spectrum of pharmacological properties, due primarily to its inhibitory effects on metabolic enzymes. | aromatic ether; beta-diketone; diarylheptanoid; enone; polyphenol | anti-inflammatory agent; antifungal agent; antineoplastic agent; biological pigment; contraceptive drug; dye; EC 1.1.1.205 (IMP dehydrogenase) inhibitor; EC 1.1.1.21 (aldehyde reductase) inhibitor; EC 1.1.1.25 (shikimate dehydrogenase) inhibitor; EC 1.6.5.2 [NAD(P)H dehydrogenase (quinone)] inhibitor; EC 1.8.1.9 (thioredoxin reductase) inhibitor; EC 2.7.10.2 (non-specific protein-tyrosine kinase) inhibitor; EC 3.5.1.98 (histone deacetylase) inhibitor; flavouring agent; food colouring; geroprotector; hepatoprotective agent; immunomodulator; iron chelator; ligand; lipoxygenase inhibitor; metabolite; neuroprotective agent; nutraceutical; radical scavenger |
sodium butyrate | organic sodium salt | EC 3.5.1.98 (histone deacetylase) inhibitor; geroprotector | |
linoleic acid | linoleic acid : An octadecadienoic acid in which the two double bonds are at positions 9 and 12 and have Z (cis) stereochemistry. Linoleic Acid: A doubly unsaturated fatty acid, occurring widely in plant glycosides. It is an essential fatty acid in mammalian nutrition and is used in the biosynthesis of prostaglandins and cell membranes. (From Stedman, 26th ed) | octadecadienoic acid; omega-6 fatty acid | algal metabolite; Daphnia galeata metabolite; plant metabolite |
8,11,14-eicosatrienoic acid | 8,11,14-Eicosatrienoic Acid: A 20-carbon-chain fatty acid, unsaturated at positions 8, 11, and 14. It differs from arachidonic acid, 5,8,11,14-eicosatetraenoic acid, only at position 5. all-cis-icosa-8,11,14-trienoic acid : An icosatrienoic acid having three cis double bonds at positions 8, 11 and 14. | fatty acid 20:3; long-chain fatty acid | fungal metabolite; human metabolite; nutraceutical |
gamma-linolenic acid | gamma-linolenic acid : A C18, omega-6 acid fatty acid comprising a linolenic acid having cis- double bonds at positions 6, 9 and 12. gamma-Linolenic Acid: An omega-6 fatty acid produced in the body as the delta 6-desaturase metabolite of linoleic acid. It is converted to dihomo-gamma-linolenic acid, a biosynthetic precursor of monoenoic prostaglandins such as PGE1. (From Merck Index, 11th ed) | linolenic acid; omega-6 fatty acid | human metabolite; mouse metabolite; plant metabolite |
alpha-linolenic acid | linolenate : A polyunsaturated fatty acid anion obtained by deprotonation of the carboxy group of either alpha- or gamma-linolenic acid. linolenic acid : A two-membered subclass of octadecatrienoic acid comprising the (9Z,12Z,15Z)- and (6Z,9Z,12Z)-isomers. Linolenic acids are nutrients essential to the formation of prostaglandins and are also used in making paints and synthetic resins. | linolenic acid; omega-3 fatty acid | micronutrient; mouse metabolite; nutraceutical |
ginkgolic acid | hydroxybenzoic acid | ||
geldanamycin | 1,4-benzoquinones; ansamycin; carbamate ester; organic heterobicyclic compound | antimicrobial agent; antineoplastic agent; antiviral agent; cysteine protease inhibitor; Hsp90 inhibitor | |
11,14,17-eicosatrienoate | all-cis-icosa-11,14,17-trienoic acid : An icosatrienoic acid having three cis- double bonds at positions 11, 14 and 17. | fatty acid 20:3; omega-3 fatty acid | |
eicosa-11,14-dienoic acid, (z,z)-isomer | (11Z,14Z)-icosadienoic acid : An icosadienoic acid with double bonds at positions 11 and 14 (both Z). icosadienoic acid : A 20-carbon, polyunsaturated fatty acid having two double bonds at unspecified positions. | icosadienoic acid | metabolite |
bms 740808 | 1-(3-aminobenzisoxazol-5'-yl)-3-trifluoromethyl-6-(2'-(3-hydroxy-N-pyrrolidinyl)methyl-(1,1')-biphen-4-yl)-1,4,5,6-tetrahydropyrazolo-(3,4-c)-pyridin-7-one: structure in first source | ||
stepholidine | stepholidine: protoberberine alkaloid isolated from opium; dual D1 receptor agonist and D2 receptor antagonist | ||
(3S,6S,9S,12R)-3-[(2S)-Butan-2-yl]-6-[(1-methoxyindol-3-yl)methyl]-9-(6-oxooctyl)-1,4,7,10-tetrazabicyclo[10.4.0]hexadecane-2,5,8,11-tetrone | oligopeptide | ||
dpc 423 | |||
l-873724 | L-873724: a selective inhibitor of cathepsin K; structure in first source | ||
eclalbasaponin i | eclalbasaponin I: has antineoplastic activity; isolated from Eclipta prostrata; structure in first source | ||
anabaenopeptin b | anabaenopeptin B: from cyanobacteria Planktothrix (Oscillatoria) rubescens | ||
dysinosin a | dysinosin A: structure in first source | ||
oleanonic acid | oleanonic acid: structure in first source | ||
nn 414 | NN 414: a hypoglycemic agent with insulin release modulating and potassium channel activating activities; structure in first source |